Exhibit 10.3

 

BACKSTOP AGREEMENT

 

This Backstop Agreement (this "Agreement") is made as of this _____ day of
October, 2020 by and among 4d pharma plc, a UK limited company (the “Company”),
Longevity Acquisition Corporation, a British Virgin Islands exempted company
("LOAC"), Whale Management Corporation, a British Virgin Islands exempted
company (the "SPAC Sponsor") and [ ], a [ ] company (the "Buyer").

 

WHEREAS, the Company has entered into that certain Merger Agreement (the "Merger
Agreement") dated October ___, 2020 by and among the Company, Dolphin Merger Sub
Limited, a British Virgin Islands exempted company and a wholly-owned subsidiary
of the Company (“Merger Sub”), and LOAC, pursuant to which LOAC will merge (the
“Merger”) with and into Merger Sub and Merger Sub will survive the Merger as a
wholly-owned subsidiary of the Company; and

 

WHEREAS, the Buyer agrees to purchase up to US$[ ] (the “Buyer Maximum
Investment”) worth of ordinary shares of LOAC (the "LOAC Ordinary Shares"), as
specified below.

 

NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth
and other good and valuable consideration, the sufficiency of which is hereby
acknowledged, the parties hereby agree as follows:

 

ARTICLE I
PURCHASE AND CLOSING

 

Section 1.01 Purchase from Third Parties. The Buyer acknowledges that after the
Company files a registration statement relating to the transactions contemplated
by the Merger Agreement, the Buyer may in its discretion acquire LOAC Ordinary
Shares in open market or private transactions from time to time. The Buyer
agrees that if the Buyer so purchases LOAC Ordinary Shares, (i) such purchases,
if any, (a) shall be made in compliance with all applicable laws, rules and
regulations, including without limitation applicable United States securities
laws, and (b) to effect such purchase, the Buyer shall not enter a bid below the
posted market offer price for such shares. The Buyer further agrees that it will
not purchase (i) LOAC Ordinary Shares prior to the filing of the registration
statement referenced in the first sentences of this Section 1.01 or (ii)
ordinary shares of the Company.

 

Section 1.02 Purchase from LOAC. Immediately after the deadline to submit the
redemption request in connection with the Merger but prior to the closing of the
Merger (the "Merger Closing"), the Buyer shall purchase from LOAC a number of
LOAC Ordinary Shares (the “Shares”) equal to the quotient obtained by dividing
(A) (i) the Commitment Amount minus (ii) (a) the number of LOAC Ordinary Shares
purchased pursuant to Section 1.01 and not redeemed and held by the Buyer as of
the Closing multiplied by (b) the Redemption Price (as defined below), by (B)
the Redemption Price. The purchase price for the Shares shall be the Redemption
Price per Share. At the closing of the purchase of the Shares pursuant to this
Section 1.02 (the “Closing”), the Buyer shall pay the aggregate purchase price
to LOAC by wire transfer of immediately available funds to an account specified
by LOAC, and LOAC shall deliver an instruction letter to its transfer agent to
deliver the Shares purchased to the Buyer. It shall be a condition to the
obligation of the Buyer on the one hand and LOAC on the other hand to consummate
the purchase of the Shares and payment of the aggregate purchase price
contemplated hereunder that the other party's representations and warranties are
true and correct at the Closing with the same effect as though made on such
date, unless waived in writing by the party to whom such representations and
warranties are made. For purposes of this Agreement, “Redemption Price” shall
mean the amount in U.S. dollars equal to the price at which each LOAC Ordinary
Share is redeemed pursuant to the redemption (as equitably adjusted for share
splits, share dividends, combinations, recapitalizations and the like) in
connection with the Merger in accordance with LOAC’s organizational documents
and the registration statement (File No. 333-226699) for LOAC’s initial public
offering.

 

 

 

 

Section 1.03 Non-Trading. The Buyer agrees that it will not redeem or transfer
any LOAC Ordinary Shares purchased pursuant to Section 1.01 of this Agreement at
or prior to the Closing.

 

Section 1.04 Commitment Consideration. As consideration for the commitment to
purchase the Shares set forth in Section 1.02 hereof, conditioned upon the
Closing occurring:

 

(a)                immediately prior to the Closing, LOAC shall issue to the
Buyer the Buyer’s Pro Rata Portion of the Commitment Ordinary Shares;

 

(b)                immediately prior to the Closing, LOAC Sponsor shall transfer
to the Buyer the Buyer’s Pro Rata Portion of the LOAC Sponsor Shares;

 

(c)                immediately prior to the Closing, LOAC Sponsor shall grant to
the Buyer an option to purchase up to the Buyer’s Pro Rata Portion of the Option
Shares at the Option Price Per Share, exercisable during the period commencing
immediately after the Closing and ending on and including the date six months
after the date of the Closing; and

 

(d)                on each monthly anniversary of the day following the Merger
Closing, the Company shall grant to the Buyer a warrant to purchase the Buyer’s
Pro Rata Portion of the Company Commitment Shares for 0.25 UK pence per share,
such warrant to be exercisable for a period of 30 days.

 

For purposes of this Section 1.04 (all share and per share amounts to be
equitably adjusted for share splits, share dividends, combinations,
recapitalizations and the like occurring after the date of this Agreement):

 

“Aggregate Redemption Amount” shall mean aggregate number of LOAC Ordinary
Shares redeemed after the date hereof multiplied by the Redemption Price.

 

“Commitment Amount” shall mean the Buyer Maximum Investment multiplied by a
fraction, the numerator of which is the Aggregate Redemption Amount and the
denominator of which is US$14,700,000.

 

“Commitment Ordinary Shares” shall mean an aggregate of 700,000 LOAC Ordinary
Shares.

 

“Company Commitment Shares” shall mean a number of ordinary shares of the
Company equal to 7,530,000 multiplied by a fraction, the numerator of which is
the number of LOAC Warrants exercised in the preceding six-month period and the
denominator of which is the aggregate number of LOAC Warrants outstanding
immediately after the Merger Closing.

 

“LOAC Sponsor Shares” shall mean an aggregate of 200,000 LOAC Ordinary Shares.

 

“LOAC Warrants” shall mean the warrants to purchase LOAC Ordinary Shares issued
by LOAC on August 28, 2018, each entitling the holder thereof to purchase
one-half of one LOAC Ordinary Share for $11.50 per whole share.

 

“Option Price Per Share” shall mean US$10.75 multiplied by the fraction, the
numerator of which is 400,000 and the denominator of which is the number of
Option Shares.

 

-2- 

 

 

“Option Shares” shall mean the ordinary shares of the Company issued to SPAC
Sponsor in the Merger as Merger consideration for 400,000 LOAC Ordinary Shares.

 

“Pro Rata Portion” shall mean the percentage obtained by dividing the Buyer
Maximum Investment by US$14,700,000.

 

ARTICLE II
REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company hereby represents and warrants to the Buyer on the date hereof and
as of the Closing that:

 

Section 2.01 Organization. Such company is duly formed in the jurisdiction of
its organization and has the requisite corporate power and authority to execute,
deliver and carry out the terms of this Agreement and to consummate the
transactions contemplated hereby.

 

Section 2.02 Authority; Non-Contravention. This Agreement has been validly
authorized, executed and delivered by such company and assuming the due
authorization, execution and delivery thereof by the other parties hereto, is a
valid and binding agreement enforceable in accordance with its terms, subject to
the general principles of equity and to bankruptcy or other laws affecting the
enforcement of creditors' rights generally. The execution, delivery and
performance of this Agreement by such company does not and will not conflict
with, violate or cause a breach of, constitute a default under, or result in a
violation of (i) any agreement, contract or instrument to which such company is
a party which would prevent such company from performing its obligations
hereunder or (ii) any law, statute, rule or regulation to which such company is
subject.

 

ARTICLE III
REPRESENTATIONS AND WARRANTIES OF LOAC AND LOAC SPONSOR

 

Each of LOAC and SPAC Sponsor hereby represents and warrants to the Buyer on the
date hereof and as of the Closing that:

 

Section 3.01 Organization. Such company is duly formed in the jurisdiction of
its organization and has the requisite corporate power and authority to execute,
deliver and carry out the terms of this Agreement and to consummate the
transactions contemplated hereby.

 

Section 3.02 Authority; Non-Contravention. This Agreement has been validly
authorized, executed and delivered by such company and assuming the due
authorization, execution and delivery thereof by the other parties hereto, is a
valid and binding agreement enforceable in accordance with its terms, subject to
the general principles of equity and to bankruptcy or other laws affecting the
enforcement of creditors' rights generally. The execution, delivery and
performance of this Agreement by such company does not and will not conflict
with, violate or cause a breach of, constitute a default under, or result in a
violation of (i) any agreement, contract or instrument to which such company is
a party which would prevent such company from performing its obligations
hereunder or (ii) any law, statute, rule or regulation to which such company is
subject.

 

Section 3.03 Valid Issuance. The Shares and the Commitment Ordinary Shares have
been duly authorized and, when issued and delivered to the Buyer pursuant to the
terms of this Agreement, will be validly issued, fully paid and non-assessable
and free and clear of any pledge, mortgage, security interest, encumbrance,
lien, charge, assessment, right of first refusal, right of pre-emption, third
party right or interest, claim or restriction of any kind or nature, except for
restrictions arising under the U.S. Securities Act of 1933, as amended (the
“Securities Act”).

 

-3- 

 

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF THE BUYER

 

The Buyer hereby represents and warrants to each of the Company, LOAC and SPAC
Sponsor on the date hereof and as of the Closing that:

 

Section 4.01 Organization. The Buyer is a corporation, duly incorporated,
validly existing and in good standing in the jurisdiction of its incorporation.
The Buyer has the requisite corporate power and authority to execute, deliver
and carry out the terms of this Agreement and to consummate the transactions
contemplated hereby.

 

Section 4.02 Authority; Non-Contravention. This Agreement has been validly
authorized, executed and delivered by the Buyer and assuming the due
authorization, execution and delivery thereof by the other parties hereto, is a
valid and binding agreement enforceable in accordance with its terms, subject to
the general principles of equity and to bankruptcy or other laws affecting the
enforcement of creditors' rights generally. The execution, delivery and
performance of this Agreement by the Buyer does not and will not conflict with,
violate or cause a breach of, constitute a default under, or result in a
violation of (i) any agreement, contract or instrument to which the Buyer is a
party which would prevent the Buyer from performing its obligations hereunder or
(ii) any law, statute, rule or regulation to which the Buyer is subject.

 

Section 4.03 Governmental Approvals. All consents, approvals, orders,
authorizations, registrations, qualifications, designations, declarations or
filings with any governmental or other authority on the part of the Buyer
required in connection with the consummation of the transactions contemplated in
the Agreement have been obtained and are effective and shall be effective as of
the Closing.

 

Section 4.04 Sophisticated Buyer. The Buyer is sophisticated in financial
matters and is able to evaluate the risks and benefits attendant to the purchase
of the Shares.

 

Section 4.05 Securities Law Compliance. The Buyer has been advised that the
offer and sale of the Shares, the Commitment Ordinary Shares and the Company
Commitment Shares (collectively, the “Acquired Securities”) has not been
registered under the Securities Act, or any other securities laws and,
therefore, none of the Acquired Securities acquired pursuant to this Agreement
can be resold unless they are registered under the Securities Act and applicable
securities laws or unless an exemption from such registration requirements is
available. The Buyer understands that the Acquired Securities will be deemed to
be "restricted securities" under the Securities Act. The Buyer is acquiring the
Acquired Securities for the Buyer's own account for investment, not as a nominee
or agent, and not with a view to, or for resale in connection with, the
distribution thereof. The Buyer represents that it is an "accredited investor"
as such term is defined in Rule 501 of Regulation D promulgated under the
Securities Act, and that the Buyer is not subject to the "Bad Actor"
disqualification, as such term is defined in Rule 506 of Regulation D
promulgated under the Securities Act.

 

Section 4.06 No Brokers. No broker, investment banker, financial advisor, finder
or other person has been retained by or is authorized to act on behalf of the
Buyer that will be entitled to any fee or commission for which the Company or
LOAC will be liable in connection with the execution of this Agreement or the
consummation of the transactions contemplated hereby.

 

-4- 

 

 

ARTICLE V
REGISTRATION RIGHTS

 

Section 5.01 Registration Rights. The Company hereby agrees with the Buyer that
the Company shall, within thirty (30) days after the Merger Closing, file a
registration statement under the Securities Act registering the resale of the
ordinary shares issued by the Company pursuant to the Merger in respect of the
Shares and the Commitment Ordinary Shares if such ordinary shares constitute
“restricted securities” or “control securities” under United States securities
laws (such “restricted” or “control” ordinary shares, if any, the “Company
Securities”); provided that if, in the good faith judgment of the board of
directors of the Company, the filing of a registration statement covering the
Company Securities would be detrimental to the Company and the board of
directors of the Company concludes, as a result, that it is in the best
interests of the Company to defer the filing of such registration statement at
such time, then (in addition to the limitations set forth in Section 5.02 below)
the Company shall have the right to defer such filing for a period of not more
than ninety (90) days after the date the Company would otherwise be obligated to
file such registration statement pursuant to this Section 5.01.

 

Section 5.02 Registration Procedures. To the extent required by Sections 5.01,
the Company will:

 

(a)                prepare and file with the SEC a registration statement with
respect to the Company Securities, and use its commercially reasonable efforts
to cause such registration statement to become effective as promptly as
practicable after the filing thereof;

 

(b)                prepare and file with the SEC such amendments to such
registration statement and supplements to the prospectus contained therein as
may be necessary to keep such registration statement effective;

 

(c)                use its commercially reasonable efforts to register or
qualify the Company Securities covered by such registration statement under such
state securities or blue sky laws of such jurisdictions as the Buyer may
reasonably request in writing within 10 days following the original filing of
such registration statement, except that the Company shall not for any purpose
be required to execute a general consent to service of process or to qualify to
do business as a foreign corporation in any jurisdiction wherein it is not so
qualified;

 

(d)                notify the Buyer, promptly after it shall receive notice
thereof, of the time when such registration statement has become effective or a
supplement to any prospectus forming a part of such registration statement has
been filed;

 

(e)                prepare and promptly file with the SEC and promptly notify
the Buyer of the filing of such amendment or supplement to such registration
statement or prospectus as may be necessary to correct any statements or
omissions if, at the time when a prospectus relating to such securities is
required to be delivered under the Securities Act, any event shall have occurred
as the result of which any such prospectus or any other prospectus as then in
effect would include an untrue statement of a material fact or omit to state any
material fact necessary to make the statements therein, in the light of the
circumstances in which they were made, not misleading; and

 

(f)                 advise the Buyer, promptly after it shall receive notice or
obtain knowledge thereof, of the issuance of any stop order by the SEC
suspending the effectiveness of such registration statement or the initiation or
threatening of any proceeding for that purpose.

 

It is a condition precedent to the obligation of the Company to take any actions
pursuant to this Article V that the Buyer shall cooperate with the Company in
providing the information necessary to effect the registration of the Buyer’s
Company Securities, including completion of customary questionnaires and
furnishing of information regarding itself, the securities of the Company held
by it and the intended method of disposition of the Company Securities. Failure
to do so will at minimum result in exclusion of the Buyer’s Company Securities
from the registration statement.

 

-5- 

 

 

Section 5.03 Expenses. All reasonable fees, costs and expenses of and incidental
to the registration effected pursuant to this Article V shall be borne by the
Company, including, without limitation, all registration, filing, and FINRA
fees, printing expenses, fees and disbursements of counsel and accountants for
the Company, and all legal fees and disbursements and other expenses of
complying with state securities or blue sky laws of any jurisdictions in which
the securities to be offered are to be registered and qualified. Notwithstanding
the foregoing, fees and disbursements of counsel and accountants for the Buyer
and any other expenses incurred by the Buyer not expressly included above,
including any taxes or stamp duties or any underwriting discounts and selling
commissions or other amounts payable to underwriter(s) or broker(s) in
connection with the sale or disposition of the Buyer’s Company Securities, shall
be borne by the Buyer.

 

ARTICLE VI
ACKNOWLEDGEMENT; WAIVER

 

Section 6.01 Acknowledgement; Waiver. The Buyer (i) acknowledges that the
Company, LOAC and LOAC Sponsor may possess or have access to material non-public
information relevant to the transactions contemplated by the Agreement which has
not been and will not be communicated to the Buyer; (ii) hereby waives any and
all claims, whether at law, in equity or otherwise, that he, she, or it may now
have or may hereafter acquire, whether presently known or unknown, against the
Company, LOAC or LOAC Sponsor or any of their respective officers, directors,
employees, agents, affiliates, subsidiaries, successors or assigns relating to
any failure to disclose any non-public information in connection with the
transactions contemplated by this Agreement, including, without limitation, to
the extent permitted by applicable law, any such claims arising under the
securities or other laws, rules and regulations of the United States, the United
Kingdom and the British Virgin Islands, and (iii) is aware that the Company,
LOAC and LOAC Sponsor are relying on the foregoing acknowledgement and waiver in
clauses (i) and (ii) above, respectively, in connection with the transactions
contemplated by this Agreement.

 

Section 6.02 Waiver Against Trust. The Buyer hereby agrees that, notwithstanding
anything to the contrary in this Agreement, the Buyer shall not now or at any
time hereafter have any right, title, interest or claim of any kind in or to any
monies in the trust account established by LOAC in connection with its initial
public offering (the “Trust Account”), to the or distributions therefrom, or
make any claim against the trust account (including any distributions
therefrom), regardless of whether such claim arises as a result of, in
connection with or relating in any way to, any proposed or actual business
relationship between LOAC or its representatives, on the one hand, and the Buyer
or its representatives, on the other hand, this Agreement or any other matter,
and regardless of whether such claim arises based on contract, tort, equity or
any other theory of legal liability (any and all such claims are collectively
referred to hereafter as the “Released Claims”). The Buyer hereby irrevocably
waives any Released Claims that the Buyer may have against the Trust Account
(including any distributions therefrom) now or in the future as a result of, or
arising out of, any negotiations, contracts or agreements with LOAC or its
representatives and will not seek recourse against the Trust Account (including
any distributions therefrom) for any reason whatsoever (including for an alleged
breach of this Agreement or any other agreement with the LOAC or its
affiliates). The Buyer agrees and acknowledges that such irrevocable waiver is
material to this Agreement and specifically relied upon by LOAC and its
affiliates to induce the Buyer to enter in this Agreement, and the Buyer further
intends and understands such waiver to be valid, binding and enforceable under
applicable law. To the extent the Buyer commences any action or proceeding based
upon, in connection with, relating to or arising out of any matter relating to
LOAC or its representatives, which proceeding seeks, in whole or in part,
monetary relief against LOAC or its representatives, the Buyer hereby
acknowledges and agrees its sole remedy shall be against funds held outside of
the Trust Account and that such claim shall not permit the Buyer (or any person
claiming on any of their behalves or in lieu of them) to have any claim against
the trust account (including any distributions therefrom) or any amounts
contained therein. For the purpose of this Section 6.2, “representative” means,
as to any person, such person’s affiliates and its and their managers,
directors, officers, employees, agents and advisors (including financial
advisors, counsel and accountants).

 

-6- 

 

 

ARTICLE VII
MISCELLANEOUS

 

Section 7.01 Termination. This Agreement shall terminate on the earlier of (i)
the date agreed by all of the parties hereto in writing, and (ii) the date the
Merger Agreement is terminated in accordance with its terms.

 

Section 7.02 Counterparts; Facsimile. This Agreement may be executed in any
number of counterparts, each of which when so executed shall be deemed to be an
original and all of which taken together shall constitute one and the same
instrument. This Agreement or any counterpart may be executed via electronic
transmission, and any such executed electronic copy shall be treated as an
original.

 

Section 7.03 Governing Law. This Agreement shall for all purposes be deemed to
be made under and shall be construed in accordance with the laws of New York.
Each of the parties hereby agrees that any action, proceeding or claim against
it arising out of or relating in any way to this Agreement shall, to the fullest
extent applicable, be brought and enforced first in the Southern District of New
York, then to such other court in the State of New York as appropriate and
irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive.
Each of the parties hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. EACH OF THE PARTIES HERETO
HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY.

 

Section 7.04 Remedies Cumulative. Each of the parties hereto acknowledges and
agrees that, in the event of any breach of any covenant or agreement contained
in this Agreement by the other party, money damages may be inadequate with
respect to any such breach and the non-breaching party may have no adequate
remedy at law. It is accordingly agreed that each of the parties hereto shall be
entitled, in addition to any other remedy to which they may be entitled at law
or in equity, to seek injunctive relief and/or to compel specific performance to
prevent breaches by the other party hereto of any covenant or agreement of such
other party contained in this Agreement. Accordingly, the Buyer hereby agrees
that each of the Company, LOAC and LOAC Sponsor is entitled to an injunction
prohibiting any conduct by the Buyer in violation of this Agreement and the
Buyer shall not seek the posting of any bond in connection with such request for
an injunction. Furthermore, in any action by the Company, LOAC or LOAC Sponsor
to enforce this Agreement, the Buyer waives its right to assert any
counterclaims and its right to assert set-off as a defense. The non-prevailing
party agrees to pay all costs and expenses, including reasonable attorneys' and
experts' fees, that the prevailing party may reasonably incur in connection with
the enforcement of this Agreement.

 

Section 7.05 Severability. If any term, provision or covenant of this Agreement
is held by a court of competent jurisdiction or other authority to be invalid,
void or unenforceable, the remainder of the terms, provisions and covenants of
this Agreement shall remain in full force and effect and shall in no way be
affected, impaired or invalidated.

 

Section 7.06 Binding Effect; No Assignment. This Agreement shall be binding upon
and inure to the benefit of the parties hereto and their respective legal
representatives and successors. Neither this Agreement nor the rights and
obligations hereunder may be assigned by any party hereto without the written
consent of each other party hereto.

 

-7- 

 

 

Section 7.07 Headings. The descriptive headings of the Sections hereof are
inserted for convenience only and do not constitute a part of this Agreement.

 

Section 7.08 Entire Agreement; Changes in Writing. This Agreement constitutes
the entire agreement among the parties hereto and supersedes and cancels any
prior agreements, representations and warranties, whether oral or written, among
the parties hereto relating to the transaction contemplated hereby. Neither this
Agreement nor any provision hereof may be changed or amended orally, but only by
an agreement in writing signed by all of the parties hereto.

 

Section 7.09 Further Assurances. Each party hereto agrees to execute and
deliver, by the proper exercise of its corporate, limited liability company,
partnership or other powers, all such other and additional instruments and
documents and do all such other acts and things as may be necessary to more
fully effectuate this Agreement.

 

(Signature pages follow)

 

-8- 

 

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date
set forth on the first page of this Agreement.

 

  4D PHARMA PLC       By:                     Name:     Title:          
LONGEVITY ACQUISITION CORPORATION       By:     Name:     Title:           WHALE
MANAGEMENT CORPORATION       By:     Name:     Title:           [BUYER]      
By:     Name:     Title: